Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Tom Greene